Pulmonary hypertension (PH) is a rare and fatal cardiopulmonary disease which disproportionately impacts women.  Despite the progress in the diagnosis, clinical care, and treatment of PH patients, unique etiological factors are still being discovered.  Iatrogenic forms of PH are one of the leading but under-appreciated causes of the disease in the modern era.

The rationale for this symposium is to leverage subject-matter expertise from international academic centers and Stanford University, engage the broader academic communities, global organizations (World Health Organization, United States Food and Drug Administration, European Medicines Agency), and stake-holders (patients, industry partners, etc) to develop a deeper understanding of “drug induced pulmonary hypertension” and establish pharmacovigilance protocols for monitoring drug safety and rapid identification of PH in at-risk populations.